149 related articles for article (PubMed ID: 35981450)
1. Analysis of dose to the macula, optic disc, and lens in relation to vision toxicities - A retrospective study using COMS eye plaques.
Oare C; Sun S; Dusenbery K; Reynolds M; Koozekanani D; Gerbi B; Ferreira C
Phys Med; 2022 Sep; 101():71-78. PubMed ID: 35981450
[TBL] [Abstract][Full Text] [Related]
2. A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using
Lee YC; Lin SC; Kim Y
Radiat Oncol; 2018 Nov; 13(1):221. PubMed ID: 30424782
[TBL] [Abstract][Full Text] [Related]
3. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
Puusaari I; Heikkonen J; Kivelä T
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma.
Dean MK; Studenski MT; Paez-Escamilla MA; Walter SD; Kwon D; Markoe AM; Harbour JW; Samuels SE
Brachytherapy; 2019; 18(3):404-410. PubMed ID: 30797699
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric and late radiation toxicity comparison between iodine-125 brachytherapy and stereotactic radiation therapy for juxtapapillary choroidal melanoma.
Krema H; Heydarian M; Beiki-Ardakani A; Weisbrod D; Xu W; Laperriere NJ; Sahgal A
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):510-5. PubMed ID: 23507292
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of choroidal melanomas treated with eye physics plaques: A 25-year review.
Le BHA; Kim JW; Deng H; Rayess N; Jennelle RL; Zhou SY; Astrahan MA; Berry JL
Brachytherapy; 2018; 17(6):981-989. PubMed ID: 30082188
[TBL] [Abstract][Full Text] [Related]
7. Ocular malignancies treated with iodine-125 low dose rate (LDR) brachytherapy at a single high-volume institution: A retrospective review.
Richards Z; Nguyen ML; Kutteh M; Ahmad S; Henson C; Firestone B; Herman TS; Herman TF
Med Dosim; 2022 Autumn; 47(3):273-279. PubMed ID: 35644778
[TBL] [Abstract][Full Text] [Related]
8. Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study: COMS Report No. 27.
Collaborative Ocular Melanoma Study Group
Ophthalmology; 2007 Jul; 114(7):1363-71. PubMed ID: 17337065
[TBL] [Abstract][Full Text] [Related]
9. Alternative dose for choroidal melanoma treated with an iodine-125 radioactive plaque: a single-institution retrospective study.
Saconn PA; Gee CJ; Greven CM; McCoy TP; Ekstrand KE; Greven KM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):844-8. PubMed ID: 20171804
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric benefit of a new ophthalmic radiation plaque.
Marwaha G; Wilkinson A; Bena J; Macklis R; Singh AD
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1226-30. PubMed ID: 22658440
[TBL] [Abstract][Full Text] [Related]
11. Lack of radiation maculopathy after palladium-103 plaque radiotherapy for iris melanoma.
Yousef YA; Finger PT
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1107-12. PubMed ID: 22172910
[TBL] [Abstract][Full Text] [Related]
12. Ruthenium brachytherapy for uveal melanomas: Factors affecting the development of radiation complications.
Pagliara MM; Tagliaferri L; Azario L; Lenkowicz J; Lanza A; Autorino R; Caputo CG; Gambacorta MA; Valentini V; Blasi MA
Brachytherapy; 2018; 17(2):432-438. PubMed ID: 29275868
[TBL] [Abstract][Full Text] [Related]
13. Optic disc dose reduction in ocular brachytherapy using
Lee YC; Lin SC; Kim Y
J Appl Clin Med Phys; 2020 Sep; 21(9):57-70. PubMed ID: 32656945
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
[TBL] [Abstract][Full Text] [Related]
15. Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: dose and dose rate effects.
Jones R; Gore E; Mieler W; Murray K; Gillin M; Albano K; Erickson B
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):989-95. PubMed ID: 11958893
[TBL] [Abstract][Full Text] [Related]
16. EyeDose: An open-source tool for using published Monte Carlo results to estimate the radiation dose delivered to the tumor and critical ocular structures for
Deufel CL; McCauley Cutsinger S; Corbin KS; Dalvin LA; Petersen IA
Brachytherapy; 2021; 20(1):189-199. PubMed ID: 33187821
[TBL] [Abstract][Full Text] [Related]
17. A practical method of estimating medium-heterogeneity corrected dose without a Monte Carlo calculation in ocular brachytherapy using
Lee YC; Nik Akhtar M; Kim Y; Jung JW
Brachytherapy; 2024; 23(3):377-386. PubMed ID: 38336557
[TBL] [Abstract][Full Text] [Related]
18. Prescribing to tumor apex in episcleral plaque iodine-125 brachytherapy for medium-sized choroidal melanoma: A single-institutional retrospective review.
Vonk DT; Kim Y; Javid C; Gordon JD; Stea B
Brachytherapy; 2015; 14(5):726-33. PubMed ID: 26051804
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Low-Dose Iodine Plaque Brachytherapy for Juxtapapillary Choroidal Melanoma.
Oellers P; Mowery YM; Perez BA; Stinnett S; Mettu P; Vajzovic L; Light K; Steffey BA; Cai J; Dutton JJ; Buckley EG; Halperin EC; Marks LB; Kirsch DG; Mruthyunjaya P
Am J Ophthalmol; 2018 Feb; 186():32-40. PubMed ID: 29199010
[TBL] [Abstract][Full Text] [Related]
20. Dose-Response and Normal Tissue Complication Probabilities after Proton Therapy for Choroidal Melanoma.
Espensen CA; Kiilgaard JF; Appelt AL; Fog LS; Herault J; Maschi C; Caujolle JP; Thariat J
Ophthalmology; 2021 Jan; 128(1):152-161. PubMed ID: 32574763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
